19 results on '"Gopal, Satish"'
Search Results
2. Frequent HIV and Young Age Among Individuals With Diverse Cancers at a National Teaching Hospital in Malawi.
- Author
-
Horner MJ, Salima A, Chilima C, Mukatipa M, Kumwenda W, Kampani C, Chimzimu F, Mukunda B, Tomoka T, Mulenga M, Nyasosela R, Chasimpha S, Dzamalala C, and Gopal S
- Subjects
- Female, Hospitals, Teaching, Humans, Malawi, Male, Middle Aged, HIV pathogenicity, HIV Infections epidemiology
- Abstract
Purpose Cancer surveillance provides a critical evidence base to guide cancer control efforts, yet population-based coverage in Africa is sparse. Hospital-based registries may help fill this need by providing local epidemiologic data to guide policy and forecast local health care needs. We report the epidemiology of patients with cancer recorded by a de novo hospital-based cancer registry at Kamuzu Central Hospital, Malawi, the sole provider of comprehensive oncology services for half the country and location of a high-volume pathology laboratory. Methods We conducted active case finding across all hospital departments and the pathology laboratory from June 2014 to March 2016. Patient demographics, tumor characteristics, treatment, and HIV status were collected. We describe epidemiology of the cancer caseload, registry design, and costs associated with registry operations. Results Among 1,446 registered patients, Kaposi sarcoma and cervical cancer were the most common cancers among men and women, respectively. Burkitt lymphoma was most common cancer among children. The current rate of pathology confirmation is 65%, a vast improvement in the diagnostic capacity for cancer through the hospital's pathology laboratory. Among leading cancer types, an alarming proportion occurred at young ages; 50% of Kaposi sarcoma and 25% of esophageal, breast, and cervical cancers were diagnosed among those younger than 40 years of age. A systematic, cross-sectional assessment of HIV status reveals a prevalence of 58% among adults and 18% among children. Conclusion We report a high caseload among typically young patients and a significant burden of HIV infection among patients with cancer. In low- and middle-income countries with intermittent, sparse, or nonexistent cancer surveillance, hospital-based cancer registries can provide important local epidemiologic data while efforts to expand population-based registration continue.
- Published
- 2018
- Full Text
- View/download PDF
3. HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.
- Author
-
Achenbach CJ, Buchanan AL, Cole SR, Hou L, Mugavero MJ, Crane HM, Moore RD, Haubrich RH, Gopal S, Eron JJ, Hunt PW, Rodriguez B, Mayer K, Saag MS, and Kitahata MM
- Subjects
- Adult, CD4 Lymphocyte Count, Female, Humans, Incidence, Male, Middle Aged, Antiretroviral Therapy, Highly Active methods, HIV isolation & purification, HIV Infections complications, HIV Infections drug therapy, Lymphoma, Non-Hodgkin epidemiology, Viral Load, Viremia complications
- Abstract
Background: The incidence of non-Hodgkin lymphoma (NHL) in human immunodeficiency virus (HIV)-infected patients remains high despite treatment with antiretroviral therapy (ART)., Methods: We evaluated NHL incidence in HIV-infected patients followed in the Centers for AIDS Research Network of Integrated Clinical Systems who started combination ART and achieved suppression of HIV. We estimated the hazard ratio for NHL by time-varying HIV viremia categories, accounting for time-varying CD4 cell count using marginal structural models., Results: We observed 37 incident NHL diagnoses during 21 607 person-years of follow-up in 6036 patients (incidence rate, 171 per 100 000 person-years; 95% confidence interval [CI], 124-236). NHL incidence was high even among patients with nadir CD4 cell count >200 cells/µL (140 per 100 000 person-years [95% CI, 80-247]). Compared with ≤50 copies/mL, hazard ratios (HRs) for NHL were higher among those with HIV viremia of 51-500 copies/mL (HR current = 1.66 [95% CI, .70-3.94]; HR 3-month lagged = 2.10 [95% CI, .84-5.22]; and HR 6-month lagged = 1.46 [95% CI, .60-3.60]) and >500 copies/mL (HR current = 2.39 [95% CI, .92-6.21]; HR 3-month lagged = 3.56 [95% CI, 1.21-10.49]; and HR 6-month lagged = 2.50 [95% CI, .91-6.84]). Current HIV RNA as a continuous variable was also associated with NHL (HR = 1.42 per log10 copies/mL [95% CI, 1.05-1.92])., Conclusions: Our findings demonstrate a high incidence of NHL among HIV-infected patients on ART and suggest a role of HIV viremia in the pathogenesis of NHL. Earlier initiation of potent ART and maximal continuous suppression of HIV viremia may further reduce NHL risk.
- Published
- 2014
- Full Text
- View/download PDF
4. State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI.
- Author
-
Engels, Eric, Shiels, Meredith, Barnabas, Ruanne, Bohlius, Julia, Brennan, Paul, Castilho, Jessica, Chanock, Stephen, Clarke, Megan, Coghill, Anna, Combes, Jean-Damien, Dryden-Peterson, Scott, DSouza, Gypsyamber, Gopal, Satish, Jaquet, Antoine, Lurain, Kathryn, Makinson, Alain, Martin, Jeffrey, Muchengeti, Mazvita, Newton, Robert, Okuku, Fred, Orem, Jackson, Palefsky, Joel, Ramaswami, Ramya, Robbins, Hilary, Sigel, Keith, Silver, Sylvia, Suneja, Gita, Yarchoan, Robert, and Clifford, Gary
- Subjects
cancer ,epidemiology ,human immunodeficiency virus ,people living with HIV ,prevention ,United States ,Humans ,HIV ,National Cancer Institute (U.S.) ,Neoplasms ,HIV Infections ,Anti-HIV Agents - Abstract
An estimated 38 million people live with human immunodeficiency virus (HIV) worldwide and are at excess risk for multiple cancer types. Elevated cancer risks in people living with HIV (PLWH) are driven primarily by increased exposure to carcinogens, most notably oncogenic viruses acquired through shared transmission routes, plus acceleration of viral carcinogenesis by HIV-related immunosuppression. In the era of widespread antiretroviral therapy (ART), life expectancy of PLWH has increased, with cancer now a leading cause of co-morbidity and death. Furthermore, the types of cancers occurring among PLWH are shifting over time and vary in their relative burden in different parts of the world. In this context, the International Agency for Research on Cancer (IARC) and the US National Cancer Institute (NCI) convened a meeting in September 2022 of multinational and multidisciplinary experts to focus on cancer in PLWH. This report summarizes the proceedings, including a review of the state of the science of cancer descriptive epidemiology, etiology, molecular tumor characterization, primary and secondary prevention, treatment disparities and survival in PLWH around the world. A consensus of key research priorities and recommendations in these domains is also presented.
- Published
- 2024
5. HIV and prior exposure to antiretroviral therapy alter tumour composition and tumour: T‐cell associations in diffuse large B‐cell lymphoma.
- Author
-
Coelho, Jenny, Roush, Sophia M., Xu, Alexander M., Puranam, Kaushik, Mponda, Marriam, Kasonkanji, Edwards, Mulenga, Maurice, Tomoka, Tamiwe, Galeotti, Jonathan, Brownlee, Amy, Ghadially, Hormas, Damania, Blossom, Painschab, Matthew, Merchant, Akil, Gopal, Satish, and Fedoriw, Yuri
- Subjects
DIFFUSE large B-cell lymphomas ,EXPOSURE therapy ,ANTIRETROVIRAL agents ,HIV infections ,HIV - Abstract
Summary: Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of lymphoma worldwide, accounting for up to 40% of new non‐Hodgkin Lymphoma (NHL) globally. People living with HIV are up to 17 times more likely to develop NHL, and as such, DLBCL is the leading cause of cancer death in this high‐risk population. While histologically indistinguishable, HIV‐associated (HIV+) and HIV‐negative (HIV−) DLBCL are molecularly distinct, and biological differences may have implications for the development of future therapeutic interventions. Further, the impact of immunologic differences in people with HIV, including preceding ART, remains largely unknown. Here, we investigate the impact of HIV infection and ART exposure on the clinical features of DLBCL and T‐cell immune response by performing imaging mass cytometry on our unique patient cohort in Malawi. In this cohort, HIV infection is positively prognostic, and HIV+/ART‐naïve patients have the best outcomes. No established biomarkers other than Ki67 are associated with HIV or ART status, and the only tumour‐intrinsic biomarkers that remain prognostic are MYC and MYC/BCL2 protein co‐expression. Finally, TCR clonality is associated with distinct tumour‐T cell interactions by HIV/ART status, indicating differential anti‐tumour immune responses. We demonstrate previously undescribed HIV and ART‐related differences in the DLBCL tumour microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Association of early HIV viremia with mortality after HIV-associated lymphoma
- Author
-
Gopal, Satish, Patel, Monita R, Yanik, Elizabeth L, Cole, Stephen R, Achenbach, Chad J, Napravnik, Sonia, Burkholder, Greer A, Reid, Erin G, Rodriguez, Benigno, Deeks, Steven G, Mayer, Kenneth H, Moore, Richard D, Kitahata, Mari M, Richards, Kristy L, and Eron, Joseph J
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Public Health ,Health Sciences ,Medical Microbiology ,Sexually Transmitted Infections ,Cancer ,Lymphoma ,Rare Diseases ,Infectious Diseases ,Lymphatic Research ,HIV/AIDS ,Hematology ,Infection ,Good Health and Well Being ,Adult ,Anti-Retroviral Agents ,CD4 Lymphocyte Count ,Female ,Hodgkin Disease ,Humans ,Lymphoma ,AIDS-Related ,Lymphoma ,Non-Hodgkin ,Male ,Middle Aged ,RNA ,Viral ,Risk Factors ,Viral Load ,Viremia ,AIDS ,Burkitt lymphoma ,diffuse large B-cell lymphoma ,HIV ,Hodgkin lymphoma ,lymphoma ,non-Hodgkin lymphoma ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology ,Biomedical and clinical sciences ,Health sciences - Abstract
ObjectiveTo examine the association between early HIV viremia and mortality after HIV-associated lymphoma.DesignMulticenter observational cohort study.SettingCenter for AIDS Research Network of Integrated Clinical Systems cohort.ParticipantsHIV-infected patients with lymphoma diagnosed between 1996 and 2011, who were alive 6 months after lymphoma diagnosis and with at least two HIV RNA values during the 6 months after lymphoma diagnosis.ExposureCumulative HIV viremia during the 6 months after lymphoma diagnosis, expressed as viremia copy-6-months.Main outcome measureAll-cause mortality between 6 months and 5 years after lymphoma diagnosis.ResultsOf 224 included patients, 183 (82%) had non-Hodgkin lymphoma (NHL) and 41 (18%) had Hodgkin lymphoma. At lymphoma diagnosis, 105 (47%) patients were on antiretroviral therapy (ART), median CD4⁺ cell count was 148 cells/μl (interquartile range 54-322), and 33% had suppressed HIV RNA (
- Published
- 2013
7. Plasmablastic lymphoma in Malawi
- Author
-
Zuze, Takondwa, Painschab, Matthew S., Seguin, Ryan, Kudowa, Evarista, Kaimila, Bongani, Kasonkanji, Edwards, Tomoka, Tamiwe, Dhungel, Bal Mukunda, Mulenga, Maurice, Chikasema, Maria, Tewete, Blessings, Ntangwanika, Asekanadziwa, Chiyoyola, Sarah, Chimzimu, Fred, Kampani, Coxcilly, Krysiak, Robert, Montgomery, Nathan D., Fedoriw, Yuri, and Gopal, Satish
- Published
- 2018
- Full Text
- View/download PDF
8. Comparison of baseline lymphoma and HIV characteristics in Malawi before and after implementation of universal antiretroviral therapy.
- Author
-
Gondwe, Yolanda, Kudowa, Evaristar, Tomoka, Tamiwe, Kasonkanji, Edwards D., Kaimila, Bongani, Zuze, Takondwa, Mumba, Noel, Kimani, Stephen, Mulenga, Maurice, Chimzimu, Fred, Kampani, Coxcilly, Randall, Cara, Lilly, Amy, Gopal, Satish, Fedoriw, Yuri, and Painschab, Matthew
- Subjects
DIFFUSE large B-cell lymphomas ,ANTIRETROVIRAL agents ,LYMPHOMAS ,HIV ,LYMPHOPROLIFERATIVE disorders ,HODGKIN'S disease - Abstract
Access to antiretroviral therapy (ART) led to epidemiological changes in human immunodeficiency virus (HIV) associated lymphoma in high-income countries such as reductions in diffuse large B-cell lymphoma (DLBCL) and stable or increased Hodgkin lymphoma (HL) and Burkitt lymphoma (BL). In 2016, Malawi implemented a universal ART (UART) policy, expanding ART eligibility to all persons living with HIV (PLWH). We compare the distribution of lymphoma subtypes and baseline HIV and prognostic characteristics for lymphoma patients in Malawi before and after implementation of UART. We enrolled patients with pathologically confirmed incident lymphoproliferative disorders into a observational clinical cohort. At diagnosis, a comprehensive clinicopathological evaluation was performed. Of 412 participants, 156 (38%) were pre-UART (2013-June 2016) and 256 (62%) post-UART (July 2016–2020). HIV prevalence was 50% in both groups. The most common pre-UART diagnoses were DLBCL [75 (48%)], low-grade non-Hodgkin lymphoma (NHL) [19 (12%)], HL [17 (11%)] and, BL [13 (8%)]. For post-UART they were DLBCL [111 (43%)], NHL [28 (11%)], BL [27 11%)] and, HL [20 (8%)]. Among PLWH, 44 (57%) pre-UART initiated ART prior to lymphoma diagnosis compared to 99 (78%) post-UART (p = 0.02). HIV-ribonucleic acid was suppressed <1000 copies/mL in 56% (33/59) pre-UART and 71% (73/103) post-UART (p = 0.05). CD4 T-cell counts were similar for both groups. We observed similar findings in the subset of participants with DLBCL. Overall, there were no significant changes in incident lymphoma subtypes (p = 0.61) after implementation of UART, but HIV was better controlled. Emerging trends bear monitoring and may have implications for prognosis and health system priority setting. Trial registration: ClinicalTrials.gov identifier:NCT02835911. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Colliding Epidemics: Research Gaps and Implementation Science Opportunities for Tobacco Use and HIV/AIDS in Low- and Middle-Income Countries.
- Author
-
Parascandola, Mark, Neta, Gila, Bloch, Michele, and Gopal, Satish
- Subjects
SUBSTANCE abuse prevention ,PREVENTION of epidemics ,ONLINE information services ,MIDDLE-income countries ,SYSTEMATIC reviews ,LOW-income countries ,TOBACCO products ,MEDLINE ,MEDICAL research ,HIV ,AIDS - Abstract
Introduction. Tobacco use is a leading cause of cancer death among people living with HIV (PLWH) worldwide, and smoking prevalence tends to be higher among PLWH. The burden of both HIV/AIDS and tobacco use is increasingly concentrated in low- and middle-income countries (LMICs), where resources to address these challenges are often limited. However, there has been limited effort to date to integrate tobacco cessation into HIV programs in LMICs. Methods. We searched the literature (searching was conducted between October 1 and December 31, 2020) using PubMed including search terms "tobacco" and "HIV" and "cessation" over the past ten years (searching for articles published between December 1, 2010, and December 1, 2020) to identify original research studies on tobacco cessation interventions conducted in LMICs for PLWH. We also conducted an analysis of NCI-funded research grants on tobacco cessation and HIV awarded during fiscal years 2010 to 2020. Results and Discussion. Existing evidence suggests that conventional tobacco cessation treatments may be less effective among PLWH. Moreover, while substantial evidence exists to support a range of cessation interventions, most of this evidence comes from HICs and is only partly applicable to the evolving social, economic, and cultural climate of many LMICs. There is an urgent need to develop, adapt, and implement effective tobacco control and cessation interventions targeted to PLWH in LMICs, as well as to generate evidence from these settings. Implementation science provides tools develop and test strategies to overcome barriers and to integrate and scale up cessation services within existing HIV treatment settings. Conclusion. There is a unique opportunity to address HIV and tobacco use in a coordinated way in LMICs by integrating evidence-based tobacco cessation into HIV programs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi.
- Author
-
Montgomery, Nathan D., Randall, Cara, Painschab, Matthew, Seguin, Ryan, Kaimila, Bongani, Kasonkanji, Edwards, Zuze, Takondwa, Krysiak, Robert, Sanders, Marcia K., Elliott, Avian, Miller, Melissa B., Kampani, Coxcilly, Chimzimu, Fred, Mulenga, Maurice, Damania, Blossom, Tomoka, Tamiwe, Fedoriw, Yuri, Dittmer, Dirk P., and Gopal, Satish
- Subjects
DIFFUSE large B-cell lymphomas ,CIRCULATING tumor DNA ,EPSTEIN-Barr virus ,HIV status ,DNA ,NANOTECHNOLOGY ,LYMPHOMAS ,GENETIC markers - Abstract
Plasma Epstein‐Barr virus (EBV) DNA measurement has established prognostic utility in EBV‐driven lymphomas, where it serves as a circulating tumor DNA marker. The value of plasma EBV measurement may be amplified in sub‐Saharan Africa (SSA), where advanced imaging and molecular technologies for risk stratification are not typically available. However, its utility in diffuse large B‐cell lymphoma (DLBCL) is less certain, given that only a subset of DLBCLs are EBV‐positive. To explore this possibility, we measured plasma EBV DNA at diagnosis in a cohort of patients with DLBCL in Malawi. High plasma EBV DNA at diagnosis (≥3.0 log10 copies/mL) was associated with decreased overall survival (OS) (P =.048). When stratified by HIV status, the prognostic utility of baseline plasma EBV DNA level was restricted to HIV‐positive patients. Unexpectedly, most HIV‐positive patients with high plasma EBV DNA at diagnosis had EBV‐negative lymphomas, as confirmed by multiple methods. Even in these HIV‐positive patients with EBV‐negative DLBCL, high plasma EBV DNA remained associated with shorter OS (P =.014). These results suggest that EBV reactivation in nontumor cells is a poor prognostic finding even in HIV‐positive patients with convincingly EBV‐negative DLBCL, extending the potential utility of EBV measurement as a valuable and implementable prognostic marker in SSA. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. High Cancer Burden Among Antiretroviral Therapy Users in Malawi: A Record Linkage Study of Observational Human Immunodeficiency Virus Cohorts and Cancer Registry Data.
- Author
-
Horner, Marie-Josèphe, Chasimpha, Steady, Spoerri, Adrian, Edwards, Jessie, Bohlius, Julia, Tweya, Hannock, Tembo, Petros, Nkhambule, Franklin, Phiri, Eddie Moffo, Miller, William C, Malisita, Kennedy, Phiri, Sam, Dzamalala, Charles, Olshan, Andrew F, and Gopal, Satish
- Subjects
HIV infection complications ,ANTIRETROVIRAL agents ,AGE distribution ,ALGORITHMS ,CONFIDENCE intervals ,REPORTING of diseases ,HEALTH services accessibility ,HIV infections ,HIV-positive persons ,KAPOSI'S sarcoma ,LONGITUDINAL method ,MEDICAL protocols ,MEDICAL records ,SCIENTIFIC observation ,RISK assessment ,CERVIX uteri tumors ,ELIGIBILITY (Social aspects) ,DISEASE incidence ,DISEASE prevalence ,ELECTRONIC health records ,EARLY detection of cancer ,ACQUISITION of data methodology ,DISEASE risk factors - Abstract
Background With antiretroviral therapy (ART), AIDS-defining cancer incidence has declined and non-AIDS–defining cancers (NADCs) are now more frequent among human immunodeficiency virus (HIV)–infected populations in high-income countries. In sub-Saharan Africa, limited epidemiological data describe cancer burden among ART users. Methods We used probabilistic algorithms to link cases from the population-based cancer registry with electronic medical records supporting ART delivery in Malawi's 2 largest HIV cohorts from 2000–2010. Age-adjusted cancer incidence rates (IRs) and 95% confidence intervals were estimated by cancer site, early vs late incidence periods (4–24 and >24 months after ART start), and World Health Organization (WHO) stage among naive ART initiators enrolled for at least 90 days. Results We identified 4346 cancers among 28 576 persons. Most people initiated ART at advanced WHO stages 3 or 4 (60%); 12% of patients had prevalent malignancies at ART initiation, which were predominantly AIDS-defining eligibility criteria for initiating ART. Kaposi sarcoma (KS) had the highest IR (634.7 per 100 000 person-years) followed by cervical cancer (36.6). KS incidence was highest during the early period 4–24 months after ART initiation. NADCs accounted for 6% of new cancers. Conclusions Under historical ART guidelines, NADCs were observed at low rates and were eclipsed by high KS and cervical cancer burden. Cancer burden among Malawian ART users does not yet mirror that in high-income countries. Integrated cancer screening and management in HIV clinics, especially for KS and cervical cancer, remain important priorities in the current Malawi context. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy
- Author
-
Achenbach, Chad J, Buchanan, Ashley L, Cole, Stephen R, Hou, Lifang, Mugavero, Michael J, Crane, Heidi M, Moore, Richard D, Haubrich, Richard H, Gopal, Satish, Eron, Joseph J, Hunt, Peter W, Rodriguez, Benigno, Mayer, Kenneth, Saag, Michael S, Kitahata, Mari M, and Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS)
- Subjects
Adult ,Male ,Lymphoma ,antiretroviral therapy ,Non-Hodgkin ,HIV Infections ,Medical and Health Sciences ,Microbiology ,Rare Diseases ,Clinical Research ,Humans ,Highly Active ,Viremia ,Cancer ,Incidence ,non-Hodgkin lymphoma ,HIV ,Evaluation of treatments and therapeutic interventions ,Hematology ,Viral Load ,Middle Aged ,Biological Sciences ,CD4 Lymphocyte Count ,Infectious Diseases ,6.1 Pharmaceuticals ,Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems ,HIV/AIDS ,Female ,Infection - Abstract
BackgroundThe incidence of non-Hodgkin lymphoma (NHL) in human immunodeficiency virus (HIV)-infected patients remains high despite treatment with antiretroviral therapy (ART).MethodsWe evaluated NHL incidence in HIV-infected patients followed in the Centers for AIDS Research Network of Integrated Clinical Systems who started combination ART and achieved suppression of HIV. We estimated the hazard ratio for NHL by time-varying HIV viremia categories, accounting for time-varying CD4 cell count using marginal structural models.ResultsWe observed 37 incident NHL diagnoses during 21 607 person-years of follow-up in 6036 patients (incidence rate, 171 per 100 000 person-years; 95% confidence interval [CI], 124-236). NHL incidence was high even among patients with nadir CD4 cell count >200 cells/µL (140 per 100 000 person-years [95% CI, 80-247]). Compared with ≤50 copies/mL, hazard ratios (HRs) for NHL were higher among those with HIV viremia of 51-500 copies/mL (HR current = 1.66 [95% CI, .70-3.94]; HR 3-month lagged = 2.10 [95% CI, .84-5.22]; and HR 6-month lagged = 1.46 [95% CI, .60-3.60]) and >500 copies/mL (HR current = 2.39 [95% CI, .92-6.21]; HR 3-month lagged = 3.56 [95% CI, 1.21-10.49]; and HR 6-month lagged = 2.50 [95% CI, .91-6.84]). Current HIV RNA as a continuous variable was also associated with NHL (HR = 1.42 per log10 copies/mL [95% CI, 1.05-1.92]).ConclusionsOur findings demonstrate a high incidence of NHL among HIV-infected patients on ART and suggest a role of HIV viremia in the pathogenesis of NHL. Earlier initiation of potent ART and maximal continuous suppression of HIV viremia may further reduce NHL risk.
- Published
- 2014
13. Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi.
- Author
-
Kaimila, Bongani, van der Gronde, Toon, Stanley, Christopher, Kasonkanji, Edwards, Chikasema, Maria, Tewete, Blessings, Fox, Paula, and Gopal, Satish
- Abstract
Background: Lymphoma is highly associated with HIV in sub-Saharan Africa (SSA), which contributes to worse outcomes relative to resource-rich settings, and frequent failure of first-line chemotherapy. However, there are no second-line treatment descriptions for adults with relapsed or refractory lymphoma (RRL) in SSA. Methods: We describe HIV+ and HIV- patients with RRL receiving salvage chemotherapy in Malawi. Patients were prospectively treated at a national teaching hospital in Lilongwe, with the modified EPIC regimen (etoposide, prednisolone, ifosfamide, cisplatin) between June 2013 and May 2016, after failing prior first-line chemotherapy. Results: Among 21 patients (18 relapsed, 3 refractory), median age was 40 years (range 16-78), 12 (57%) were male. Thirteen patients (62%) were HIV+, of whom 12 (92%) were on antiretroviral therapy (ART) at initiation of salvage chemotherapy, with median CD4 cell count 139 cells/|uL (range 12-529) and 11 (85%) with suppressed HIV RNA. Median number of EPIC cycles was 3 (range 1-6), and the commonest toxicity was grade 3/4 neutropenia in 19 patients (90%). Fifteen patients responded (3 complete, 12 partial, overall response rate 71%), but durations were brief. Median overall survival was 4.5 months [95% confidence interval (CI) 2.4-5.6]. However, three patients, all HIV+, experienced sustained remissions. Tolerability, response, and survival did not differ by HIV status. Conclusions: The appropriateness and cost-effectiveness of this approach in severely resource-limited environments is uncertain, and multifaceted efforts to improve first-line lymphoma treatment should be emphasized, to reduce frequency with which patients require salvage chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Cancer trials in sub-Saharan Africa: Aligning research and care.
- Author
-
Gopal, Satish
- Subjects
- *
CANCER treatment , *CLINICAL trials , *CANCER research , *ANTINEOPLASTIC agents , *ANTIRETROVIRAL agents , *RESEARCH funding , *TUMORS - Abstract
Satish Gopal discusses the challenges of deliverable cancer care and cancer trials in sub-Saharan Africa as well as a potential framework for overcoming these challenges. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
15. High rates of cervical cancer among HIV-infected women at a referral hospital in Malawi.
- Author
-
Kohler, Racquel E., Tang, Jennifer, Gopal, Satish, Chinula, Lameck, Hosseinipour, Mina C., Liomba, N. George, and Chiudzu, Grace
- Subjects
CERVICAL cancer research ,DISEASE prevalence ,HIV-positive women ,MEDICAL referrals ,PUBLIC health - Abstract
Cervical cancer is the most common cancer among women in Malawi. National guidelines recommend screening women aged 30-45 years every five years; however, no specific recommendations exist for women with HIV. We aimed to assess the frequency of high-grade dysplasia (CIN 2 or CIN3) and cervical cancer among women in central Malawi and to examine associations with CIN2+ (CIN2/3 or cancer). We extracted cervical Pap smear, biopsy, loop electrosurgical excision procedure and uterine specimen reports from a hospital pathology database from November 2012 to November 2013. We used logistic regression to estimate associations with CIN2+. We reviewed specimens from 824 women; we excluded 194 with unknown HIV status, leaving 630 in the analytic sample. Twelve percent had high-grade dysplasia and 109 women (17%) had cancer. Twenty-five percent of high-grade dysplasia cases and 35% of cancers occurred among women outside recommended screening ages. The odds of having CIN2+ were 6.55 times (95% CI 4.44-9.67) greater for HIV+ women. High-grade dysplasia and cervical cancer are very common among Malawian women, especially HIV+ women. HIV infection was strongly associated with CIN2+. Expanding screening to women not covered by current guidelines could avert a substantial proportion of cervical cancer cases in Malawi. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi.
- Author
-
Gopal, Satish, Fedoriw, Yuri, Kaimila, Bongani, Montgomery, Nathan D., Kasonkanji, Edwards, Moses, Agnes, Nyasosela, Richard, Mzumara, Suzgo, Varela, Carlos, Chikasema, Maria, Makwakwa, Victor, Itimu, Salama, Tomoka, Tamiwe, Kamiza, Steve, Dhungel, Bal M., Chimzimu, Fred, Kampani, Coxcilly, Krysiak, Robert, Richards, Kristy L., and Shea, Thomas C.
- Subjects
- *
LYMPHOMA treatment , *CANCER chemotherapy , *ANTIRETROVIRAL agents , *DOXORUBICIN , *CYCLOPHOSPHAMIDE - Abstract
There are no prospective studies of aggressive non-Hodgkin lymphoma (NHL) treated with CHOP in sub-Saharan Africa. We enrolled adults with aggressive NHL in Malawi between June 2013 and May 2015. Chemotherapy and supportive care were standardized, and HIV+ patients received antiretroviral therapy (ART). Thirty-seven of 58 patients (64%) were HIV+. Median age was 47 years (IQR 39–56), and 35 (60%) were male. Thirty-five patients (60%) had stage III/IV, 43 (74%) B symptoms, and 28 (48%) performance status ≥2. B-cell NHL predominated among HIV+ patients, and all T-cell NHL occurred among HIV- individuals. Thirty-one HIV+ patients (84%) were on ART for a median 9.9 months (IQR 1.1–31.7) before NHL diagnosis, median CD4 was 121 cells/μL (IQR 61–244), and 43% had suppressed HIV RNA. HIV+ patients received a similar number of CHOP cycles compared to HIV- patients, but more frequently developed grade 3/4 neutropenia (84% vs 31%, p = 0.001), resulting in modestly lower cyclophosphamide and doxorubicin doses with longer intervals between cycles. Twelve-month overall survival (OS) was 45% (95% CI 31–57%). T-cell NHL (HR 3.90, p = 0.017), hemoglobin (HR 0.82 per g/dL, p = 0.017), albumin (HR 0.57 per g/dL, p = 0.019), and IPI (HR 2.02 per unit, p<0.001) were associated with mortality. HIV was not associated with mortality, and findings were similar among patients with diffuse large B-cell lymphoma. Twenty-three deaths were from NHL (12 HIV+, 11 HIV-), and 12 from CHOP (9 HIV+, 3 HIV-). CHOP can be safe, effective, and feasible for aggressive NHL in Malawi with and without HIV. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
17. Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi.
- Author
-
Gopal, Satish, Liomba, N George, Montgomery, Nathan D, Moses, Agnes, Kaimila, Bongani, Nyasosela, Richard, Chikasema, Maria, Dhungel, Bal M, Kampani, Coxcilly, Sanders, Marcia K, Krysiak, Robert, Dittmer, Dirk P, and Fedoriw, Yuri
- Abstract
Introduction: Clinical reports of multicentric Castleman disease (MCD) from sub-Saharan Africa (SSA) are scarce despite high prevalence of HIV and Kaposi sarcoma-associated herpesvirus (KSHV). Our objective is to describe characteristics and survival for HIV-associated MCD patients in Malawi. To our knowledge, this is the first HIV-associated MCD case series from the region. Methods: We describe HIV-positive patients with MCD in Lilongwe, and compare them to HIV-associated lymph node Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL) patients treated at our centre. All patients were enrolled into a prospective longitudinal cohort study at a national teaching hospital and cancer referral centre serving half of Malawi's 16 million people. We included adult patients≥18 years of age with HIV-associated MCD (n=6), lymph node KS (n=5) or NHL (n=31) enrolled between 1 June 2013 and 31 January 2015. Results and discussion: MCD patients had a median age of 42.4 years (range 37.2–51.8). All had diffuse lymphadenopathy and five had hepatosplenomegaly. Concurrent KS was present for one MCD patient, and four had performance status ≥3. MCD patients had lower median haemoglobin (6.4 g/dL, range 3.6–9.3) than KS (11.0 g/dL, range 9.1–12.0, p=0.011) or NHL (11.2 g/dL, range 4.5–15.1, p=0.0007). Median serum albumin was also lower for MCD (2.1 g/dL, range 1.7–3.2) than KS (3.7 g/dL, range 3.2–3.9, p=0.013) or NHL (3.4 g/dL, range 1.8–4.8, p=0.003). All six MCD patients were on antiretroviral therapy (ART) with median CD4 count 208 cells/µL (range 108–1146), and all with HIV RNA <400 copies/mL. Most KS and NHL patients were also on ART, although ART duration was longer for MCD (56.4 months, range 18.2–105.3) than KS (14.2 months, range 6.8–21.9, p=0.039) or NHL (13.8 months, range 0.2–98.8, p=0.017). Survival was poorer for MCD patients than lymph node KS or NHL. Conclusions: HIV-associated MCD occurs in Malawi, is diagnosed late and is associated with high mortality. Improvements in awareness, diagnostic facilities, treatment and supportive care are needed to address this likely under-recognized public health problem in SSA. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Early Experience after Developing a Pathology Laboratory in Malawi, with Emphasis on Cancer Diagnoses.
- Author
-
Gopal, Satish, Krysiak, Robert, Liomba, N. George, Horner, Marie-Josephe, Shores, Carol G., Alide, Noor, Kamiza, Steve, Kampani, Coxcilly, Chimzimu, Fred, Fedoriw, Yuri, Dittmer, Dirk P., Hosseinipour, Mina C., and Hoffman, Irving F.
- Subjects
- *
CANCER diagnosis , *CLINICAL pathology , *LOGISTIC regression analysis , *BIOLOGICAL specimens , *CYTOLOGY , *CANCER research , *HOSPITALS - Abstract
Background: Despite increasing cancer burden in Malawi, pathology services are limited. We describe operations during the first 20 months of a new pathology laboratory in Lilongwe, with emphasis on cancer diagnoses. Methods and Findings: We performed a cross-sectional study of specimens from the Kamuzu Central Hospital pathology laboratory between July 1, 2011 and February 28, 2013. Patient and specimen characteristics, and final diagnoses are summarized. Diagnoses were categorized as malignant, premalignant, infectious, other pathology, normal or benign, or nondiagnostic. Patient characteristics associated with premalignancy and malignancy were assessed using logistic regression. Of 2772 specimens, 2758 (99%) with a recorded final diagnosis were included, drawn from 2639 unique patients. Mean age was 38 years and 63% were female. Of those with documented HIV status, 51% had unknown status, and 36% with known status were infected. Histologic specimens comprised 91% of cases, and cytologic specimens 9%. Malignant diagnoses were most common overall (n = 861, 31%). Among cancers, cervical cancer was most common (n = 117, 14%), followed by lymphoma (n = 91, 11%), esophageal cancer (n = 86, 10%), sarcoma excluding Kaposi sarcoma (n = 75, 9%), and breast cancer (n = 61, 7%). HIV status was known for 95 (11%) of malignancies, with HIV prevalence ranging from 9% for breast cancer to 81% for cervical cancer. Increasing age was consistently associated with malignancy [bivariable odds ratio 1.24 per decade increase (95% CI 1.19–1.29) among 2685 patients with known age; multivariable odds ratio 1.33 per decade increase (95% CI 1.14–1.56) among 317 patients with known age, gender, and HIV status], while HIV infection and gender were not. Conclusions: Despite selection and referral bias inherent in these data, a new pathology laboratory in Lilongwe has created a robust platform for cancer care and research. Strategies to effectively capture clinical information for pathologically confirmed cancers can allow these data to complement population-based registration. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
19. Multicentric Castleman's disease in Malawi.
- Author
-
Gopal, Satish, Fedoriw, Yuri, Montgomery, Nathan D., Kampani, Coxcilly, Krysiak, Robert, Sanders, Marcia K., Dittmer, Dirk P., and Liomba, N. George
- Subjects
- *
CASTLEMAN'S disease , *HIV , *FEVER , *MALARIA , *WEIGHT loss , *KAPOSI'S sarcoma-associated herpesvirus - Abstract
The article describes a case of multicentric Castleman's disease in a 51-year-old man in Malawi. The patient presented with a history of 6 months of diffuse progressive lymphadenopathy and hepatosplenomegaly with fever, chills, night sweats, and weight loss. Information on Kaposi sarcoma-associated herpesvirus (KSHV) that causes the plasmablastic variant of multicentric Castleman's disease is presented.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.